DaVita Inc. $DVA Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in shares of DaVita Inc. (NYSE:DVA) by 16.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 126,765 shares of the company’s stock after selling 24,548 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in DaVita were worth $28,203,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of DVA. Berkshire Hathaway Inc purchased a new position in shares of DaVita during the 2nd quarter valued at approximately $6,425,269,000. BlackRock Inc. acquired a new position in shares of DaVita in the second quarter worth about $547,520,000. Invesco Ltd. grew its position in shares of DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after acquiring an additional 32,358 shares during the period. Morgan Stanley raised its holdings in DaVita by 5.1% in the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock worth $167,807,000 after purchasing an additional 71,156 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after buying an additional 636,191 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Up 1.5%

Shares of DVA opened at $182.00 on Friday. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The stock has a fifty day simple moving average of $209.28 and a two-hundred day simple moving average of $184.28. The company has a market capitalization of $11.61 billion, a PE ratio of 14.89, a price-to-earnings-growth ratio of 0.46 and a beta of 0.83.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DVA has been the topic of a number of research analyst reports. Truist Financial dropped their price target on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $201.00 to $220.00 in a report on Friday, August 7th. UBS Group lifted their price target on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Raymond James Financial set a $220.00 price objective on DaVita in a report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $265.00 price target on shares of DaVita in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $221.75.

Insider Activity

In related news, insider Kathleen Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.90% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.